Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma
-
By
-
Kun Lv
-
Zhiqiao Liang
-
Kuankuan Wu
-
Yao Ma
-
Kangyi Yang
-
Wenbo Liu
-
Huijuan Wu
-
November 14, 2025
-
Clinical Scorecard: Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma
At a Glance
| Category | Detail |
|---|
| Condition | Refractory Secondary Glaucoma |
| Key Mechanisms | Elevated intraocular pressure (IOP) due to identifiable factors leading to glaucomatous optic neuropathy. |
| Target Population | Patients with uncontrolled IOP exceeding 21 mmHg or requiring multiple anti-glaucoma medications. |
| Care Setting | University-based glaucoma clinic. |
Key Highlights
- XEN-45 Gel Stent offers a minimally invasive alternative to traditional glaucoma surgeries.
- Effective for various forms of refractory secondary glaucoma including uveitic and steroid-induced glaucoma.
- Implantation techniques include ab interno and ab externo methods, with ab externo gaining popularity.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of secondary glaucoma requires evidence of disease progression and elevated IOP.
Management
- Initial treatment involves medical therapy; surgical options are for cases uncontrolled by medications.
Monitoring & Follow-up
- Regular follow-up for IOP measurement and assessment of visual field defects is essential.
Risks
- Traditional surgeries pose risks of complications such as hypotony and bleb leaks.
Patient & Prescribing Data
Patients with refractory secondary glaucoma, including those with uveitis, trauma, and steroid-induced conditions.
XEN-45 gel stents have shown effectiveness in managing IOP with fewer complications compared to traditional methods.
Clinical Best Practices
- Utilize minimally invasive techniques to reduce surgical trauma and recovery time.
- Ensure thorough pre-operative assessment of conjunctival health and prior surgical history.
References
